Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CINACALCET HYDROCHLORIDE vs ACYLANID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allosteric activator of the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing sensitivity to extracellular calcium and reducing parathyroid hormone (PTH) secretion.
Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Hypercalcemia in patients with parathyroid carcinoma,Severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
Heart failure,Atrial fibrillation,Atrial flutter
30 mg orally once daily, titrate every 2-4 weeks to a maximum of 180 mg once daily to achieve target intact parathyroid hormone (i PTH) level.
0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.
Terminal elimination half-life: 30–40 hours in patients with normal renal function; prolonged to 42–83 hours in moderate to severe hepatic impairment. Steady-state reached within 7 days.
Terminal half-life 33–36 hours (anuric patients up to 110 hours); requires dose adjustment in renal impairment.
Hepatic via CYP3A4, CYP2D6, and CYP1A2; major metabolites are inactive.
Hepatic metabolism via hydrolysis and conjugation; not significantly metabolized by CYP enzymes.
Renal: 80% (as metabolites), Fecal: 15%, Biliary: negligible.
Renal (≈70% as unchanged drug), biliary/fecal (≈30%)
97% bound to albumin.
25–30% bound to albumin.
Approximately 1.7 L/kg (1000 L for 70 kg person), indicating extensive tissue distribution.
7.5–10 L/kg; wide distribution indicating extensive tissue binding.
76–82% (oral); food increases AUC by 50–80%.
Oral: 70–85% (variable, dependent on gastrointestinal absorption).
No dose adjustment required for any degree of renal impairment, including end-stage renal disease (ESRD) on dialysis.
GFR <30 m L/min: reduce dose by 50% and extend dosing interval to every 12-24 hours. GFR 30-50 m L/min: consider 25% dose reduction. Monitor digoxin levels.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate to severe hepatic impairment (Child-Pugh B or C): reduce starting dose to 30 mg daily and monitor i PTH and serum calcium closely.
Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use with caution, reduce dose by 50% and monitor levels. Not recommended in severe hepatic impairment.
Not established for pediatric patients; safety and efficacy in children have not been determined.
Loading dose: 10-15 mcg/kg IV over 5 minutes. Maintenance: 5-10 mcg/kg orally every 8-12 hours. Maximum daily dose: 250 mcg in children <2 years, 500 mcg in older children.
No specific dose adjustment recommended; clinical studies included patients aged 65 and older, but no overall differences in safety or efficacy were observed. Use with caution due to potential for increased sensitivity.
Initiate with 50% of usual adult dose due to reduced renal function and increased sensitivity. Maximum loading dose: 0.2 mg IV. Maintenance: 0.1 mg every 12 hours. Monitor electrolytes and ECG.
None.
None.
Hypocalcemia: Can cause life-threatening hypocalcemia; monitor serum calcium levels frequently.,Seizures: Increased risk, especially in patients with history of seizure disorder.,QT interval prolongation: Hypocalcemia may exacerbate QT prolongation; monitor ECGs in patients with risk factors.,Hypotension and worsening heart failure: Cases reported, especially in patients with impaired cardiac function.,Adynamic bone disease: May develop with oversuppression of PTH; monitor bone-specific alkaline phosphatase.
Risk of digitalis toxicity; monitor renal function and electrolytes; caution in hypokalemia, hypomagnesemia, and hypercalcemia.
Hypocalcemia,Known hypersensitivity to cinacalcet or any component of the formulation
Ventricular fibrillation,Hypersensitivity to cardiac glycosides,Digitalis toxicity
Take with food or immediately after a dialysis treatment. Avoid high-calcium meals (e.g., dairy) within 2 hours of dosing as calcium binds cinacalcet and reduces absorption. No other dietary restrictions; maintain consistent calcium intake per renal diet.
Avoid high-potassium foods (bananas, oranges, spinach) unless directed; hypokalemia increases toxicity. Take with food to reduce GI upset. Do not take with high-fiber meals as may reduce absorption.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cinacalcet produced fetal toxicity (reduced fetal weight, increased incidence of skeletal variations) at doses 0.5-4 times the maximum human dose. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus.
Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Second and third trimesters: Maternal toxicity (arrhythmias, electrolyte disturbances) may cause fetal hypoxia or growth restriction. Avoid toxicity. Category C.
No data on presence in human milk. In lactating rats, cinacalcet was excreted in milk with milk:plasma ratio approximately 2.4. Potential for serious adverse reactions in nursing infants; decision to discontinue nursing or drug should consider importance of drug to mother.
Acylanid is excreted into breast milk in low amounts (M/P ratio not established; estimated <1% of maternal dose). No adverse effects reported in nursing infants. Use with caution, monitor infant for bradycardia or arrhythmias.
No specific dosing adjustments are established due to lack of pharmacokinetic data in pregnancy. Serum calcium and PTH should be monitored frequently to guide dosing, as volume distribution and clearance may change. Generally, maintain lowest effective dose to control hyperparathyroidism.
Increased volume of distribution and renal clearance in pregnancy may reduce serum levels; monitor drug levels and adjust dose to maintain therapeutic range (0.5-2 ng/m L). Start at lower doses if hypokalemia or preeclampsia present.
Monitor serum calcium within 1 week of initiation or dose adjustment; cinacalcet may cause hypocalcemia, so do not start if calcium <8.4 mg/d L. Correct elevated PTH in CKD patients with i PTH >300 pg/m L on dialysis; not for use in non-dialysis CKD. QTc prolongation risk: obtain baseline ECG and monitor electrolytes, especially if on QT-prolonging drugs. Nausea and vomiting are common; administer with food or after dialysis session to improve tolerance.
Acylanid (lanatoside C) is a digitalis glycoside with rapid onset (IV 10-30 min) and moderate duration; use in atrial fibrillation with rapid ventricular response, especially in acute settings. Monitor renal function due to renal elimination; toxicity risk increases with hypokalemia, hypomagnesemia, hypercalcemia. Adjust dose in renal impairment (Cr Cl <50 m L/min). Therapeutic drug monitoring: target serum level 0.5-2 ng/m L (drawn >6-8 hours post-dose).
Take cinacalcet with food or right after a dialysis session to reduce stomach upset.,Do not stop taking this medication suddenly; consult your doctor if you have side effects.,Report symptoms of low calcium such as muscle cramps, numbness, or tingling in fingers/toes.,Tell your doctor if you have a history of seizures or liver problems.,Avoid taking strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) unless prescribed; inform all healthcare providers.
Take exactly as prescribed; do not skip doses or double up. Missed dose: take if within 12 hours, otherwise skip.,Monitor for signs of toxicity: nausea, vomiting, diarrhea, visual disturbances (yellow-green halos, blurred vision), confusion, irregular heartbeat.,Avoid OTC medications without consulting prescriber, especially antacids, laxatives, and antiarrhythmics.,Keep regular appointments for blood tests (digoxin level, kidney function, electrolytes).,Report weight gain >2 lbs/day, swelling, shortness of breath, or palpitations.
"Cinacalcet, a potent CYP3A4 inhibitor, significantly decreases the metabolism of Indinavir, a CYP3A4 substrate. This leads to elevated plasma concentrations of Indinavir, increasing the risk of dose-related toxicities such as nephrolithiasis, acute interstitial nephritis, and hepatotoxicity. The interaction may require Indinavir dose reduction and close monitoring for adverse effects."
"Duloxetine, a moderate inhibitor of CYP2D6 and CYP1A2, can reduce the metabolism of cinacalcet, a CYP2D6 and CYP1A2 substrate, leading to increased plasma concentrations of cinacalcet. This elevation may enhance the pharmacodynamic effects of cinacalcet, including a greater reduction in parathyroid hormone (PTH) and increased risk of hypocalcemia. Clinically, patients may experience symptoms such as paresthesias, muscle cramps, or cardiac arrhythmias due to electrolyte disturbances."
"Nitrofural, an antibacterial agent, is a potent inhibitor of CYP450 enzymes, particularly CYP3A4 and CYP1A2. Cinacalcet is extensively metabolized by CYP3A4 and, to a lesser extent, CYP1A2. Concomitant use of Nitrofural with Cinacalcet significantly reduces the systemic clearance of Cinacalcet, leading to elevated plasma concentrations. This increases the risk of dose-dependent adverse effects such as hypocalcemia, QT prolongation, and seizures."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CINACALCET HYDROCHLORIDE vs ACYLANID, answered by our medical review team.
CINACALCET HYDROCHLORIDE is a Calcimimetic that works by Allosteric activator of the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing sensitivity to extracellular calcium and reducing parathyroid hormone (PTH) secretion.. ACYLANID is a Cardiac Glycoside that works by Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CINACALCET HYDROCHLORIDE and ACYLANID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CINACALCET HYDROCHLORIDE is: 30 mg orally once daily, titrate every 2-4 weeks to a maximum of 180 mg once daily to achieve target intact parathyroid hormone (i PTH) level.. The standard adult dose of ACYLANID is: 0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CINACALCET HYDROCHLORIDE and ACYLANID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CINACALCET HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cinacalcet produced fetal toxicity (reduced fetal weight, increased incidence of skeletal variat. ACYLANID is classified as Category C. Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.